Progenitor cell therapy for heart disease.

摘要: Many cell types are currently being studied as potential sources of cardiomyocytes for transplantation therapy to repair and regenerate damaged myocardium. The question remains which progenitor represents the best candidate. Bone marrow-derived cells endothelial have been tested in clinical studies. These safe, but their cardiogenic is controversial. functional benefits observed probably due enhanced angiogenesis, reduced ventricular remodeling, or cytokine-mediated effects that promote survival endogenous cells. Human embryonic stem represent an unlimited source great differentiation potential, each step must be tightly controlled high risk teratoma formation. cells, however, confront ethical barriers there a graft rejection. last two problems can avoided by using induced pluripotent (iPS), autologously derived, formation remains. Cardiac advantage cardiac committed, important questions remain unanswered, such what marker identify isolate these cells? To date different markers used adult also recognize outside heart. Thus, it cannot determined whether identified heart resident present since fetal life extracardiac colonized after injury. Developmental studies multipotent progenitors, unknown specific progenitors when expressed regeneration dependent on stability transplanted into host myocardium electromechanical coupling with Finally, promotion regenerative processes mobilizing complementary approach therapy.